Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue
Valink is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue. They focus on bispecific antibody-drug conjugates (ADCs) that improve treatment efficacy and minimize side effects.